Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens

1 Jun 2020

Abstract excerpt

BACKGROUND: In vivo targeting of human papillomavirus (HPV) derived antigens to dendritic cells might constitute an efficient immunotherapeutic strategy against cervical cancer. In previous works, we have shown that the extra domain A from murine fibronectin (mEDA) can be used to target antigens to toll-like receptor 4 (TLR4) expressing dendritic cells and induce strong antigen-specific immune responses. In the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cervical Cancer and HPV Research
Share to Immunotherapy and Immune Responses
Share to Reproductive tract infections research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32581060
DOI: 10.1136/jitc-2020-000704

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigensPMID 32581060Read ↗

EDA-E7 activated DCs induces specific cytotoxic T lymphocyte immune responses against HPV expressing cervical cancer in human settingSemantic proximity Read ↗

Design, Immune Responses and Anti-Tumor Potential of an HPV16 E6E7 Multi-Epitope VaccineSemantic proximity Read ↗

DNA vaccines for cervical cancer: from bench to bedsideSemantic proximity Read ↗

Therapeutic vaccines against HPV16-associated tumors. Minireview.Semantic proximity Read ↗

Design of a multi-epitope vaccine against cervical cancer using immunoinformatics approachesSemantic proximity Read ↗

Human Papillomavirus Type 16 E6/E7-specific Cytotoxic T Lymphocytes for Adoptive Immunotherapy of HPV-associated MalignanciesSemantic proximity Read ↗

Enhanced Cytotoxic CD8 T Cell Priming Using Dendritic Cell-Expressing Human Papillomavirus-16 E6/E7-p16INK4 Fusion Protein with Sequenced Anti-Programmed Death-1.Semantic proximity Read ↗

Anti-tumor DNA vaccines based on the expression of human papillomavirus-16 E6/E7 oncoproteins genetically fused with the glycoprotein D from herpes simplex virus-1Semantic proximity Read ↗

[What clinicians should know about human papilloma virus vaccines].Semantic proximity Read ↗

Development of a DNA Vaccine Targeting Human Papillomavirus Type 16 Oncoprotein E6Semantic proximity Read ↗

Identification of human MHC-I HPV18 E6/E7-specific CD8 + T cell epitopes and generation of an HPV18 E6/E7-expressing adenosquamous carcinoma in HLA-A2 transgenic miceSemantic proximity Read ↗

Adenovirus vector‐based prime‐boost vaccination via heterologous routes induces cervicovaginal CD8+ T cell responses against HPV16 oncoproteinsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.